Search Results
Search for other papers by Heike Hoyer-Kuhn in
Google Scholar
PubMed
Search for other papers by Angela Huebner in
Google Scholar
PubMed
Search for other papers by Anette Richter-Unruh in
Google Scholar
PubMed
Search for other papers by Markus Bettendorf in
Google Scholar
PubMed
Search for other papers by Tilman Rohrer in
Google Scholar
PubMed
Search for other papers by Klaus Kapelari in
Google Scholar
PubMed
St.Anna Kinderspital, Medical University of Vienna, Vienna, Austria
Search for other papers by Stefan Riedl in
Google Scholar
PubMed
Search for other papers by Klaus Mohnike in
Google Scholar
PubMed
Search for other papers by Helmuth-Günther Dörr in
Google Scholar
PubMed
Search for other papers by Friedrich-Wilhelm Roehl in
Google Scholar
PubMed
Search for other papers by Katharina Fink in
Google Scholar
PubMed
Search for other papers by Reinhard W Holl in
Google Scholar
PubMed
Search for other papers by Joachim Woelfle in
Google Scholar
PubMed
Objective
Treatment of classic congenital adrenal hyperplasia (CAH) is necessary to compensate for glucocorticoid/mineralocorticoid deficiencies and to suppress androgen excess. Hydrocortisone (HC) is preferred in growing children with classic CAH but recommendations regarding dosage/administration are inconsistent. The aim of this study was to evaluate HC dosing in children with CAH in relation to chronological age, sex, and phenotype based on a multicenter CAH registry.
Design
The CAH registry was initiated in 1997 by the AQUAPE in Germany. On December 31st 2018, data from 1571 patients were included.
Methods
A custom-made electronic health record software is used at the participating centers. Pseudonymized data are transferred for central analysis. Parameters were selected based on current guidelines. Descriptive analyses and linear regression models were implemented with SAS 9.4.
Results
We identified 1288 patients on exclusive treatment with hydrocortisone three times daily (604 boys; median age 7.2 years; 817 salt-wasting phenotype, 471 simple-virilizing phenotype). The mean (lower-upper quartiles) daily HC dose (mg/m² body surface area) was 19.4 (18.9–19.8) for patients <3 months (n = 329), 15.0 (14.6–15.3) for age ≥3–12 months (n = 463), 14.0 (13.7–14.3) for age 1–5.9 years (n = 745), 14.2 (14.0–14.5) for age 6 years to puberty entry (n = 669), and 14.9 (14.6–15.2) during puberty to 18 years (n = 801). Fludrocortisone was administered in 74.1% of patients with a median daily dosage of 88.8 µg.
Conclusion
Our analyses showed that still a high proportion of children are treated with HC doses higher than recommended. This evaluation provides comprehensive information on nationwide hydrocortisone substitution dosages in children with CAH underlining the benefit of systematic data within a registry to assess daily practice.
Search for other papers by Lisette van Alewijk in
Google Scholar
PubMed
Search for other papers by Kirsten Davidse in
Google Scholar
PubMed
Search for other papers by Karlijn Pellikaan in
Google Scholar
PubMed
Search for other papers by Judith van Eck in
Google Scholar
PubMed
Academic Centre for Growth, Erasmus University Medical Centre, Rotterdam, the Netherlands
Dutch Growth Research Foundation, Rotterdam, the Netherlands
Search for other papers by Anita C S Hokken-Koelega in
Google Scholar
PubMed
Diabeter, National Diabetes Care and Research Centre, Rotterdam, the Netherlands
Search for other papers by Theo C J Sas in
Google Scholar
PubMed
Department of Paediatric Endocrinology, Leiden University Medical Centre, Leiden, the Netherlands
Search for other papers by Sabine Hannema in
Google Scholar
PubMed
Search for other papers by Aart J van der Lely in
Google Scholar
PubMed
Academic Centre for Growth, Erasmus University Medical Centre, Rotterdam, the Netherlands
Search for other papers by Laura C G de Graaff in
Google Scholar
PubMed
-011-9640-9 ) 37 Merke D Kabbani M Congenital adrenal hyperplasia: epidemiology, management and practical drug treatment . Paediatric Drugs 2001 3 599 – 611 . ( https://doi.org/10.2165/00128072-200103080-00005 ) 38 Betterle C Presotto F Furmaniak
AP-HP.Nord-Université de Paris, Hôpital Universitaire Robert Debré, Unité d’Épidémiologie Clinique, Inserm, Paris, France
Search for other papers by Enora Le Roux in
Google Scholar
PubMed
Search for other papers by Florence Menesguen in
Google Scholar
PubMed
Search for other papers by Isabelle Tejedor in
Google Scholar
PubMed
Search for other papers by Marc Popelier in
Google Scholar
PubMed
Search for other papers by Marine Halbron in
Google Scholar
PubMed
Search for other papers by Pauline Faucher in
Google Scholar
PubMed
Search for other papers by Sabine Malivoir in
Google Scholar
PubMed
Search for other papers by Graziella Pinto in
Google Scholar
PubMed
Search for other papers by Juliane Léger in
Google Scholar
PubMed
Search for other papers by Stephane Hatem in
Google Scholar
PubMed
Search for other papers by Michel Polak in
Google Scholar
PubMed
Search for other papers by Christine Poitou in
Google Scholar
PubMed
Search for other papers by Philippe Touraine in
Google Scholar
PubMed
Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies . Lancet 2007 370 1453 – 145 7 . ( https://doi.org/10.1016/S0140-6736(0761602-X) ) 17 Hoffmann
Search for other papers by Kaiyu Pan in
Google Scholar
PubMed
Search for other papers by Chengyue Zhang in
Google Scholar
PubMed
Search for other papers by Xiaocong Yao in
Google Scholar
PubMed
Search for other papers by Zhongxin Zhu in
Google Scholar
PubMed
DG Egger M Pocock SJ Gotzsche PC Vandenbroucke JP & STROBE Initiative . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies . Lancet 2007 370
Division of Endocrinology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
Search for other papers by Volha V Zhukouskaya in
Google Scholar
PubMed
APHP, Department of Endocrinology and Diabetology for Children, Bicêtre Paris Saclay Hospital, Le Kremlin-Bicêtre, France
Search for other papers by Anya Rothenbuhler in
Google Scholar
PubMed
Search for other papers by Annamaria Colao in
Google Scholar
PubMed
IRCCS SDN, Naples, Italy
Search for other papers by Carolina Di Somma in
Google Scholar
PubMed
APHP, Department of Endocrinology and Reproductive Diseases, Bicêtre Paris-Saclay Hospital, Le Kremlin-Bicêtre, France
Paris Sud – Paris Saclay University, Faculté de Médecine, Le Kremlin-Bicêtre, France
Search for other papers by Peter Kamenický in
Google Scholar
PubMed
APHP, Department of Molecular Genetics, Pharmacogenetics and Hormonology, Bicêtre Paris-Saclay Hospital, Le Kremlin-Bicêtre, France
Search for other papers by Séverine Trabado in
Google Scholar
PubMed
Hôpital Necker EnfantsMalades APHP, INSERM U1151, Paris, France
Search for other papers by Dominique Prié in
Google Scholar
PubMed
Search for other papers by Christelle Audrain in
Google Scholar
PubMed
Search for other papers by Anna Barosi in
Google Scholar
PubMed
Search for other papers by Christèle Kyheng in
Google Scholar
PubMed
APHP, Department of Endocrinology and Diabetology for Children, Bicêtre Paris Saclay Hospital, Le Kremlin-Bicêtre, France
APHP, Department of Adolescent Medicine, Bicêtre Paris Saclay Hospital, Le Kremlin-Bicêtre, France
Search for other papers by Anne-Sophie Lambert in
Google Scholar
PubMed
APHP, Department of Endocrinology and Diabetology for Children, Bicêtre Paris Saclay Hospital, Le Kremlin-Bicêtre, France
Paris Sud – Paris Saclay University, Faculté de Médecine, Le Kremlin-Bicêtre, France
Search for other papers by Agnès Linglart in
Google Scholar
PubMed
epidemiology worldwide . Gastroenterology Clinics of North America 2016 571 – 579 . ( https://doi.org/10.1016/j.gtc.2016.07.012 ) 18 Vanhelst J Baudelet JB Fardy PS Béghin L Mikulovic J Ulmer Z . Prevalence of overweight, obesity